What Дюспаталин treats: Main Uses and Benefits

Дюспаталин (mebeverine hydrochloride) is a medicine that belongs to a class of drugs known as antispasmodics. It is commonly used across conditions presenting with acute episodes related to the gastrointestinal (GI) tract.

Mebeverine may be part of symptomatic management for conditions characterized by periods of heightened symptoms, such as Irritable Bowel Syndrome (IBS). It is applied in addressing symptoms related to physical discomfort, like abdominal cramping, and other associated symptoms that become more disruptive during flare-ups. Mebeverine is indicated in the management of the irritable bowel syndrome and is often applied in contexts involving heightened systemic burden.

This treatment may assist with addressing symptoms of increased neurological or muscular activity and supports patients during episodes of heightened discomfort. In settings marked by temporary physiological imbalance, mebeverine contributes to easing the overall symptom load during symptomatic phases. This medication provides supportive relief when symptoms interfere with daily functioning. Mebeverine is applied in addressing symptom clusters that may become intense or disruptive, and assists with maintaining functional stability.

---

Quick Fact: Support for Symptoms Related to Physical Discomfort

Regulatory References

1. indicated in the management of the irritable bowel syndrome

The use of Duspatalin (mebeverine hydrochloride) is generally intended for adults and adolescents from a specific age, typically 10 or 12 years and over, for the symptomatic treatment of Irritable Bowel Syndrome (IBS) and related gastrointestinal spasms.

Contraindications and Patient Groups

Patient Group	Status and Restriction	Key Reason
Children	Not generally recommended	Dosage forms (e.g., 200 mg capsules) are unsuitable for those under 10 or 12 years of age, or under 3 years entirely due to lack of clinical data.
Allergy/Hypersensitivity	Cannot use	Hypersensitivity to mebeverine or any of the inactive ingredients (excipients).
Pregnancy	Cautionary, generally not recommended	Limited data on safety for the developing fetus; use only if potential benefit outweighs risk, based on a physician’s advice.
Breastfeeding	Generally not recommended	Safety is not established; it is not known if the active substance or its metabolites pass into breast milk in amounts that could harm the infant.
Rare Hereditary Disorders	Cannot use	The medicine often contains sugars like lactose or sucrose, making it unsuitable for patients with certain conditions like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Patients with severe liver or kidney problems should consult a physician, though specific dose adjustments are not always deemed necessary based on available post-marketing data. It is crucial to inform your doctor if new symptoms develop or current symptoms worsen.

The official regulatory documents for mebeverine hydrochloride (the active ingredient in Дюспаталин) define the product's interaction profile by formally stating the limitations of available data and documenting the findings of specific studies.

Regulatory studies strictly document the absence of interaction between mebeverine and ethanol (alcohol). This is the only specific interaction finding explicitly detailed in the official label's interaction section.

---

Regulatory Status of Documented Interactions

Interaction Category	Official Regulatory Statement
Drug-Drug Interactions	The regulatory label explicitly states that no formal interaction studies have been performed with other medicinal products.
Contraindications	No medicinal products are formally listed as contraindicated due to a specific drug-drug interaction risk.
Metabolic/Transporter Effects	No specific pharmacokinetic changes, such as CYP-mediated inhibition or induction, or transporter-based interactions are documented.
Administration Rules	No mandatory timing rules or dose separation windows for co-administration are specified in the official prescribing information.

Consequently, the official documentation does not list any substances that increase or decrease mebeverine plasma levels. While formal posology studies in the elderly or in patients with hepatic or renal impairment have not been conducted, available post-marketing data has not indicated a specific heightened interaction risk for these populations.

How Дюспаталин Works: The Mechanism of Action

The action of Mebeverine (Дюспаталин) is that of a musculotropic antispasmodic. The mechanism involves the modulation of smooth muscle activity in the gut wall.

---

Direct Blockade of L-Type Calcium Channels

The primary mechanistic domain involves the non-specific blockade of L-type Ca^2+ channels on intestinal smooth muscle cells. This action inhibits the influx of extracellular calcium ions ( Ca^2+), which are essential for contraction. By chemically interfering with this molecular step, the drug results in the physiological sequence of muscle relaxation.

---

Selective Suppression of Hypercontractility

The core cascade involves the interference with excitation-contraction coupling: reduced Ca^2+ prevents the activation of key enzymes like myosin light-chain kinase, stopping the phosphorylation of myosin. This mechanism preferentially acts upon the pathological, hypercontractile state (spasms) while preserving the necessary, normal gut movements (eutonia). The process maintains muscle tone within a regulated range.

---

Localized Action and Minimal Systemic Effect

The mechanism is predominantly peripheral, meaning the physiological effect is localized to the gastrointestinal tract. The mechanism’s minimal muscarinic receptor activity and peripheral localization result in a focused physiological effect confined to the target tissue.

Official Administration Guidelines for Mebeverine Hydrochloride

Mebeverine hydrochloride (Дюспаталин) is administered strictly by the oral route and is available in two primary dosage forms for adult use: 135 mg film-coated tablets and 200 mg slow-release capsules. The labeled instructions for use define both the dosing frequency and the required context for administration.

---

Standard Adult Dosing Regimens

Dosage Form	Unit Dose and Frequency	Administration Rule	Maximum Dose (per day)
135 mg Tablets	One tablet three times a day (TID)	Taken preferably 20 minutes before meals	Not to exceed three tablets (405 mg)
200 mg Capsules	One capsule twice a day (BID)	Taken preferably before the morning and evening meals	Not to exceed two capsules (400 mg)

---

Procedural and Duration Instructions

To ensure the functional design of the medicine is maintained, both the tablets and the slow-release capsules must be swallowed whole with a sufficient amount of water, such as at least 100 mL, and should not be chewed or crushed. The duration of use is not subject to a strict time limit and may be continued until the desired therapeutic effect is obtained. Following a period of symptom control over several weeks, the dosage may be gradually reduced.

In the event of a missed dose, the dose should not be taken in addition to the next scheduled dose; the regular regimen should simply be continued. For special populations, no specific dosage adjustment is deemed necessary for older adults or patients with renal or hepatic impairment. However, use is not recommended in children and adolescents below 18 years due to insufficient data on safety and efficacy for the 135 mg tablet form.

Research evidence / Overview of studies for Дюспаталин

Evidence for use in Irritable Bowel Syndrome (IBS)

The research for Дюспаталин consists primarily of short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-Analyses. These studies were conducted to explore how symptoms related to the smooth muscles of the gut changed over time in adults diagnosed with Irritable Bowel Syndrome, a condition characterized by fluctuating or episodic manifestations. Findings describe patterns observed in the studies related to changes in abdominal pain.

Studies monitored several key outcomes, including the severity and frequency of abdominal pain and overall discomfort. However, some scientific reviews, particularly older meta-analyses, reported that the evidence related to an overall global measure of symptom improvement was mixed. These analyses often indicated that the data did not show a statistically significant difference compared to a placebo for global improvement. More recent reviews have described patterns of change measured during the study period for abdominal pain and abnormal bowel habits, contributing to the broader evidence landscape.

Research in Functional Abdominal Pain (FAP) and Related Conditions

The agent Дюспаталин was studied for related functional gastrointestinal disorders, particularly focusing on studies involving adolescents and older children who meet criteria for Irritable Bowel Syndrome or Functional Abdominal Pain – Not Otherwise Specified (FAP-NOS). These controlled trials were applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns.

In a recent randomized trial involving adolescents, research examined outcomes related to a defined metric of symptom change (e.g., a reduction in pain intensity and frequency). Research describes that the measured symptom change rates in the Дюспаталин group showed patterns related to those in the placebo group in this specific population for these defined outcomes.

Key Limitations and Areas of Research Uncertainty

Follow-up durations were limited across the majority of controlled research, meaning there is limited information for long-term outcomes. Long-term effects are not fully established. The scientific analysis also highlights that older studies included in some reviews had sample sizes that were modest and displayed methodological flaws. Overall, data for certain groups or extended time intervals remain insufficient to fully describe the evidence landscape.

Key Studies & References TGA Regulatory Decision Summary: Mebeverine registration document for the management of the irritable bowel syndrome (IBS)

Common questions about Дюспаталин (FAQ)

Q: Why is Дюспаталин often prescribed for Irritable Bowel Syndrome (IBS)?

A: Дюспаталин is a type of medicine known as a musculotropic antispasmodic. This means its action involves the direct modulation of the smooth muscle activity of the gastrointestinal tract, leading to relaxation. It is prescribed because this action is intended to relieve spasms and associated abdominal pain, which are core features of Irritable Bowel Syndrome (IBS).

Q: What should be avoided when taking Дюспаталин?

A: Regulatory studies strictly document the absence of an interaction between mebeverine, the active ingredient, and ethanol (alcohol). Beyond this, official information states that formal interaction studies have not been performed with other medicinal products. Information regarding the use of this medicine is based on the guidance provided by a healthcare professional.

Q: Does Дюспаталин interact with common vitamins or supplements?

A: The official regulatory label states that formal interaction studies have not been conducted with other medicinal products, which includes common supplements and vitamins. Therefore, the official documentation does not contain specific information regarding the interaction of this medicine with supplements or vitamins.

Q: How does the slow-release form of Дюспаталин work?

A: Дюспаталин is manufactured in specialized slow-release capsules, which are designed to control the rate at which the active ingredient is released into the body. This design is intended to provide a sustained and consistent effect over time, which allows for less frequent dosing compared to the standard tablet formulation.

Q: What are the main goals of treatment with Дюспаталин according to official sources?

A: The general purpose is to alleviate common abdominal distress, particularly cramping. By reducing spastic muscle activity in the gut, the goal is to specifically reduce the severity of pain and discomfort that originates from these involuntary movements.

Q: Is it okay to take Дюспаталин every day?

A: Official administration guidelines state that use of the medicine may be continued until the desired therapeutic effect—symptom relief—is obtained. Following a period where symptoms are well-controlled, official guidance describes that the dosage may be gradually reduced.

Q: How quickly does Дюспаталин start to work after taking it?

A: Pharmacokinetic studies, which monitor how the body processes the medicine, describe that the concentration of the active substance typically reaches its maximum concentration in the body's plasma approximately one to three hours after the dose is administered orally.

Q: How long do the effects of Дюспаталин usually last?

A: Regulatory documents describe the half-life of the drug’s primary metabolites (the substances it breaks down into) as being around two hours. The half-life is a scientific measure of the time it takes for the concentration of the substance in the body to be reduced by half.

Q: What are the most common things people feel as side effects from Дюспаталин?

A: Official safety information lists documented adverse reactions primarily related to immune system disorders (such as anaphylactic reactions) and skin disorders (such as hives or swelling). All reported reactions are based on spontaneous post-marketing reports, meaning their frequency is formally classified as 'Not known' because the rate cannot be estimated from the available data.

Q: Can Дюспаталин cause sleepiness or drowsiness?

A: Official product information, including the assessment of its effect on the ability to drive or operate machinery, indicates that the medicine is not likely to cause significant drowsiness. Official information indicates that the medicine is not likely to affect the ability to drive or operate machinery.

Q: Can you drink coffee while taking Дюспаталин?

A: Official documentation does not specify any mandatory rules regarding the co-administration of food or beverages, including caffeine, outside of timing the dose around meals. No formal interaction studies have been performed with coffee or similar products.

Q: Is Дюспаталин safe to take with common stomach acid reducers?

A: The official regulatory label explicitly states that no formal interaction studies have been performed with other medicinal products. This means there is no formal documentation of a specific drug-drug interaction risk between this medicine and acid reducers.

Q: Is Дюспаталин safe for older adults (the elderly)?

A: The medicine's official administration guidelines state that no specific dosage adjustment is deemed necessary for older adults. They are included in the patient group that typically takes the standard adult dosage.

Q: Are there any food restrictions when using Дюспаталин?

A: The administration guidelines specify that the medicine should be taken preferably 20 minutes before meals. However, regulatory documents do not list any specific foods or beverages that must be restricted or avoided while using this medication.

Q: Does Дюспаталин treat the cause of the problem or just the symptoms?

A: The medicine's action is to target and modulate the smooth muscle activity in the gut wall, specifically suppressing the excessive contractions known as spasms. Since spasms are the core symptoms of functional bowel disorders, its mechanism addresses the physiological driver of the pain, which is the muscular hypercontractility (excessive tightening).

Q: Do studies support the use of Дюспаталин for stomach discomfort?

A: Research has examined the use of the medicine for symptoms related to the smooth muscles of the gut. Studies focused on conditions like Irritable Bowel Syndrome, monitoring outcomes related to abdominal pain and overall discomfort, which are components of general stomach discomfort.

Q: Is there a generic version of Дюспаталин available?

A: The defining active ingredient in Дюспаталин is Mebeverine Hydrochloride. Mebeverine is the non-proprietary (generic) name for the active chemical substance used in the medicine.

Q: Can Дюспаталин be used for general bloating?

A: Official indications describe the medicine for the symptomatic treatment of conditions like Irritable Bowel Syndrome (IBS). Symptoms that have been documented to be treated in these contexts include the physical sensations of bloating and excess wind (flatulence).

Q: Does taking Дюспаталин require a special diet?

A: Regulatory guidance provides rules for when to take the medicine, advising it be taken before meals. However, official documents do not state that a person must follow a specialized diet while using the medicine.

Q: Can Дюспаталин cause constipation or diarrhea?

A: The medicine is indicated for the symptomatic treatment of conditions involving altered bowel habits. These conditions are the target of the medicine's action, and they include spastic constipation and persistent diarrhea (which may occur with or without alternating constipation).

Q: Is it normal to feel a change in appetite after starting Дюспаталин?

A: A decrease in appetite, sometimes referred to as anorexia, has been listed as a reported side effect of the medicine. The frequency of this side effect is formally classified as 'Not known' because the rate cannot be estimated from the available data.

Q: Can someone with kidney issues use Дюспаталин?

A: Official administration guidelines state that no specific dosage adjustment is deemed necessary for patients with renal (kidney) impairment.

Q: Can Дюспаталин cause dry mouth?

A: Dry mouth is not listed as one of the documented adverse reactions in the official safety classification. The documented reactions are primarily limited to disorders of the immune system and the skin and subcutaneous tissue.

Q: Are there any warnings about driving or operating machinery while using Дюспаталин?

A: Official information states that the medicine is not likely to affect a person's ability to drive a vehicle or operate machinery. This information is based on the known pharmacological profile and post-marketing experience.

Q: Does Дюспаталин interact with hormonal birth control pills?

A: The regulatory label explicitly states that no formal interaction studies have been performed with any other medicinal products. This means there is no specific official documentation addressing an interaction with hormonal birth control pills.

Q: If Дюспаталин is stopped, do the original symptoms come back immediately?

A: Administration guidelines suggest the dosage may be gradually reduced following a period of sustained symptom control. Regulatory guidance includes information that patients should not stop the medicine without consulting a health professional.

Q: Can Дюспаталин be taken on an empty stomach?

A: The official administration rule is to take the medicine preferably 20 minutes before meals. This timing is typically when the stomach is considered empty.

Q: Does Дюспаталин have a 'peak' effect time after taking a dose?

A: Pharmacokinetic studies have examined the concentration of the drug's metabolites in the plasma. These studies describe that the concentration reaches its maximum measurable level in the body's plasma approximately one to three hours after a dose is taken orally.

Q: Is Дюспаталин a long-term or short-term treatment?

A: The duration of use is described in administration guidelines as continuing until the desired therapeutic effect is achieved. This indicates that its use is intended to be contingent on symptom control, rather than following a fixed long-term or short-term schedule.

Q: Can Дюспаталин be used for trapped wind or gas pain?

A: The medicine is indicated for the symptomatic treatment of conditions like Irritable Bowel Syndrome (IBS). Official documents confirm that symptoms documented to be treated in this context include the physical sensation of trapped wind and gas pain (flatulence).

How to Store and Dispose of Дюспаталин?

The storage and disposal of this medicine are governed by official regulatory standards to ensure product stability and environmental safety.

Mandatory Storage Conditions

Condition	Requirement (Official Labeling)
Temperature	Store at a temperature not exceeding 30 C.
Environment	Protect from light and moisture; keep in the original package.
Handling	Do not refrigerate or freeze the medicine.

Disposal and Safety Rules

Rule	Requirement (Official Labeling)
Child Safety	Must be kept out of the sight and reach of children.
Disposal	Dispose of unused or expired product according to local pharmaceutical waste regulations.
Environment	Must not be discharged into sewer systems or released into the environment.

These constraints ensure the medication maintains its chemical properties throughout its documented shelf-life. Disposal must adhere to specific standards for pharmaceutical waste.